Cipla gets final approval for generic version of Albendazole Tablets
Deepthi | Myequity news | Date : 21-09-2018 20:30:00 IST
Cipla Limited has received final approval for its Abbreviated New Drug Application (ANDA) for Albendazole Tablets 200mg from the United States Food and Drug Administration (US FDA). Cipla’s Albendazole Tablets 200mg is AB-rated generic therapeutic equivalent version of Impax Laboratories, Inc.’s, Albenza®.
Albendazole Tablets 200mg is an anthelmintic drug indicated for use in Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.
According to IQVIA (IMS Health), Albenza® had US sales of approximately $99M for the 12-month period ending July 2018. The product is available for shipping immediately. About Cipla:
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Its 44 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Mar’18), 4th largest in the pharma private market in South Africa (IQVIA MAT Jun’18), and is among the most dispensed generic players in the US.